Flora Natura® La Ruche: Concentration - Examen +
Integratore alimentare dichiarato in Francia, notifica n. 2018-9-310, decisione del 13 settembre 2018
Flora Natura® La Ruche: Concentration - Examen +, dell'azienda Scientia Natura Distribution, è un integratore alimentare dichiarato in Francia. Stato: dichiarato in Francia, commercializzazione possibile. Ingredienti principali: Ginkgo biloba 1.000 mg al giorno, Eschscholzia californica 1.000 mg al giorno, Gelée royale, miel, Pollen. 1 norma d’uso si applica ai suoi ingredienti (limiti e avvertenze).
- Marca
- Flora Natura
- Responsabile dell’immissione in commercio
- Scientia Natura Distribution
- Stato
- Dichiarato in Francia, commercializzazione possibile: l’amministrazione non si è opposta alla dichiarazione (non è né un’autorizzazione né una valutazione della sicurezza)
- Forma
- Fiala
- Dose giornaliera
- Modalità d’uso
Testo originale in francese.
Prendre 1 ampoule par jour avant un repas. Il est conseillé de diluer l’ampoule dans un verre d’eau.
- Sconsigliato (secondo il fabbricante)
- Donne che allattano, Bambini (sotto i 12 anni), Donne in gravidanza, In trattamento con anticoagulanti, In trattamento con antidepressivi, In trattamento farmacologico, Uso prolungato
- Obiettivi dichiarati dal fabbricante (non sono indicazioni autorizzate)
- Concentrazione
Notifica 290956, procedura Article 15. Compl’Alim, dichiarazioni di integratori alimentari, consultato il 15 novembre 2026.
Composizione dichiarata
Piante
| Pianta | Parte | Preparazione | Al giorno |
|---|---|---|---|
| Ginkgo biloba L. | Feuille | Extrait fluide aqueux | 1.000 mg |
| Eschscholzia californica Cham. | Parties aériennes fleurie | Extrait fluide aqueux | 1.000 mg |
Altri ingredienti attivi
| Nome | Al giorno |
|---|---|
| Gelée royale | non dichiarata |
| miel | non dichiarata |
| Pollen | non dichiarata |
Elenco della dichiarazione, decisione dell'amministrazione del (Compl’Alim, dichiarazioni di integratori alimentari).
Avvertenze dell’etichetta
Testo originale in francese.
Consultez votre médecin en cas de prise simultanée d'anticoagulants. L'emplois chez les personnes sous traitement antidépresseur est déconseillé. L'emploi chez les femmes enceintes et allaitantes est déconseillé.Aspetti normativi
- Conditions légales
Ginkgo biloba L.: L'étiquetage des compléments alimentaires qui contiennent la feuille de la plante Ginkgo biloba L. doit comporter un avertissement avec la teneur suivante: "Consultez votre médecin en cas de prise simultanée d'anticoagulants."
Fonte: Decreti francesi del 9 maggio 2006 (nutrienti), del 24 giugno 2014 (piante) e del 26 settembre 2016 (altre sostanze), raccolta LEGI consolidata, arrêté du 24 juin 2014, annexe I.
Queste informazioni riprendono la dichiarazione del fabbricante all’amministrazione (DGAL). Non dicono se il prodotto sia efficace e non sostituiscono il parere di un medico o farmacista, in particolare in gravidanza o durante un trattamento.
Avvertenze ufficiali (Health Canada)
Health Canada pubblica avvertenze su questi ingredienti:
- Ginkgo biloba L.
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
GINKGO - GINKGO BILOBA
Via di somministrazione: Oral
Precauzioni e avvertenze
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).
Fonti citate da Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
- WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
- OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).
Fonti citate da Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Controindicazioni
Do not use if you are having a surgery (Gardner and McGuffin 2013).
Fonti citate da Health Canada (1)
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).
Fonti citate da Health Canada (3)
- Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Revisione sistematica
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.
- Eschscholzia californica Cham.
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
CALIFORNIA POPPY - ESCHSCHOLZIA CALIFORNICA
Via di somministrazione: Oral
Precauzioni e avvertenze
Condizione di applicazione: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (Berardi et al. 2002; Dipiro et al. 2002).
Fonti citate da Health Canada (2)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.; 2002.
Condizione di applicazione: Other uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condizione di applicazione: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Brinker 2010; Mills and Bone 2005).
Fonti citate da Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
When using this product avoid taking with alcohol or products that cause drowsiness and/or with analgesic properties (Brinker 2010; Mills and Bone 2005; Hoffmann 2003).
Fonti citate da Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (EMA 2015; Berardi et al. 2002).
Fonti citate da Health Canada (2)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- EMA 2015: European Medicines Agency. European Union herbal monograph on Eschscholzia californica Cham., herba London. (UK): Committee on Herbal Medicinal Products (HMPC); 2015. [Accessed 2024 March 1]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-eschscholzia-californica-cham-herba_en.pdf.
Controindicazioni
Do not use if you are pregnant (Brinker 2010; Blumenthal et al. 2000).
Fonti citate da Health Canada (2)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gelée royale
Leggere l'avvertenza, quando si applica e gli studi citati
Testo originale ufficiale in inglese.
ROYAL JELLY
Via di somministrazione: Oral
Precauzioni e avvertenze
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Controindicazioni
Do not use if you have a history of asthma or allergies (TGA 2001; Leung et al. 1997; Harwood et al. 1996; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995; Bullock 1994).
Fonti citate da Health Canada (8)
- Bullock RJ. Fatal royal-jelly induced asthma. Medical Journal of Australia 1994;160:44. PubMed Caso clinico
- Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Caso clinico
- Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
- Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
- Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Caso clinico
- Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Caso clinico
- TGA 2001: Australian Therapeutic Goods Administration. CMEC 28: Complementary Medicines Evaluation Committee, Extracted Ratified Minutes twenty-eight Meeting, 27-28 July 2001. Australian Government Department of Health and Aging, Sydney, Australia; 2001. [Accessed 2025 February 5]. Available from: https://www.tga.gov.au/sites/default/files/cmec-minutes-28.pdf
- Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
Reazioni avverse note
Stop use if hypersensitivity/allergy occurs (Leung et al. 1997; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995).
Fonti citate da Health Canada (6)
- Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
- Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
- Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Caso clinico
- Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Caso clinico
- Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
- Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Caso clinico
Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.
Marca : Flora Natura
Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.